Tyra Biosciences, Inc. (NASDAQ:TYRA) Forecasted to Post FY2025 Earnings of ($2.15) Per Share

Tyra Biosciences, Inc. (NASDAQ:TYRAFree Report) – Equities research analysts at HC Wainwright issued their FY2025 EPS estimates for shares of Tyra Biosciences in a report released on Wednesday, March 20th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($2.15) for the year. HC Wainwright currently has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.96) per share.

Several other brokerages have also recently weighed in on TYRA. Wedbush reaffirmed an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research note on Thursday. Bank of America cut shares of Tyra Biosciences from a “buy” rating to a “neutral” rating and decreased their target price for the company from $25.00 to $15.00 in a research note on Friday, December 15th.

Check Out Our Latest Research Report on Tyra Biosciences

Tyra Biosciences Stock Performance

Shares of TYRA stock opened at $16.72 on Thursday. The company has a market capitalization of $878.13 million, a P/E ratio of -10.39 and a beta of 1.19. The company’s 50 day moving average price is $17.09 and its two-hundred day moving average price is $14.55. Tyra Biosciences has a 52 week low of $10.38 and a 52 week high of $20.67.

Insiders Place Their Bets

In other Tyra Biosciences news, COO Daniel Bensen sold 1,501 shares of Tyra Biosciences stock in a transaction on Monday, February 12th. The shares were sold at an average price of $20.00, for a total transaction of $30,020.00. Following the completion of the transaction, the chief operating officer now directly owns 451,480 shares of the company’s stock, valued at $9,029,600. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 15,816 shares of company stock valued at $298,165 over the last ninety days. 18.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tyra Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of TYRA. Vanguard Group Inc. raised its stake in Tyra Biosciences by 3.6% in the fourth quarter. Vanguard Group Inc. now owns 758,967 shares of the company’s stock valued at $10,512,000 after purchasing an additional 26,383 shares in the last quarter. Wellington Management Group LLP raised its stake in Tyra Biosciences by 8.8% during the fourth quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock worth $1,419,000 after acquiring an additional 8,324 shares in the last quarter. Barclays PLC raised its stake in Tyra Biosciences by 667.2% during the fourth quarter. Barclays PLC now owns 19,227 shares of the company’s stock worth $266,000 after acquiring an additional 16,721 shares in the last quarter. Nuveen Asset Management LLC raised its stake in Tyra Biosciences by 37.1% during the fourth quarter. Nuveen Asset Management LLC now owns 25,713 shares of the company’s stock worth $356,000 after acquiring an additional 6,957 shares in the last quarter. Finally, Kynam Capital Management LP bought a new stake in shares of Tyra Biosciences during the fourth quarter worth about $4,712,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

(Get Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies.

Featured Stories

Earnings History and Estimates for Tyra Biosciences (NASDAQ:TYRA)

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.